TCR engineered T cells for solid tumor immunotherapy.

ABSTRACT: T cell immunotherapy remains an attractive approach for cancer immunotherapy. T cell immunotherapy mainly employs chimeric antigen receptor (CAR)- and T cell receptor (TCR)-engineered T cells. CAR-T cell therapy has been an essential breakthrough in treating hematological malignancies. TCR-T cells can recognize antigens expressed both on cell surfaces and in intracellular compartments. Although TCR-T cells have not been approved for clinical application, a number of clinical trials have been performed, particularly for solid tumors. In this article, we summarized current TCR-T cell advances and their potential advantages for solid tumor immunotherapy.

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC9210724 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature